SNK-6 Cell Line细胞株-BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

SNK-6 Cell Line

Name: SNK-6    Tissue: extranodal, blood_bone_marrow, haematopoietic_and_lymphoid_tissue    Disease: lymphoma, leukaemia, lymphoid_neoplasm

Studies on nasal T/natural killer (NK)–cell
lymphoma have been hampered by its tendency to cause necrosis. Thus, the
establishment of cell lines of this neoplasm would seem to be valuable. This
study attempted to establish cell lines from primary lesions of this tumor, and
successfully obtained 2 novel Epstein-Barr virus (EBV)–positive cell lines,
SNK-6 and SNT-8, by means of high-dose recombinant interleukin 2. Flow
cytometry showed that SNK-6 had an NK-cell phenotype, CD3⁻CD4⁻CD8⁻CD19⁻CD56⁺T-cell receptor (TCR) α/β⁻TCR γ/δ⁻, whereas SNT-8 was CD3⁺CD4⁻CD8⁻CD19⁻CD56⁺TCR α/β⁻TCR γ/δ⁺. These were consistent with immunophenotypes of their original tumors,
and the cell lines had monoclonal EBV clones identical to ones in their
original tumors. Thus, the cell lines developed from cells forming the primary
lesions. Genotypic analysis showed that SNK-6 had unrearranged TCR and
immunoglobulin heavy-chain genes, supporting the conclusion that SNK-6 was of
NK-cell lineage. On the other hand, SNT-8 had rearranged TCR β-, γ-, and
δ-chain genes, and together with its phenotype, SNT-8 proved to be a γδ T-cell
line. This is the first report of the establishment of cell lines from primary
lesions of nasal T/NK cell lymphomas, and the results demonstrated that there
are at least 2 lineages, NK- and γδ T-cell, in this neoplasm. Moreover, it has
been suggested that nasal T/NK cell lymphomas of these lineages may belong to
the same clinicopathologic entity because both types of cases shared common
clinical and histopathologic features.

Complete Growth Medium: 90%RPMI 1640+10%FBS+100 U/ml penicillin G
sodium (option); 100 µg/ml streptomycin sulfate (option);

Application: Cells and cancer research

BioVector NTCC Inc.